Navigation Links
Top-Line Efficacy Data Presented from Phase 2 Trial of Alemtuzumab in Multiple Sclerosis
Date:10/15/2007

erse reactions are cytopenias, infusion reactions, and immunosuppression/infections.

About Genzyme

One of the world's leading biotechnology companies, Genzyme is dedicated to making a major positive impact on the lives of people with serious diseases. Since 1981, the company has grown from a small start-up to a diversified enterprise with more than 9,500 employees in locations spanning the globe and 2006 revenues of $3.2 billion. In 2007, Genzyme was chosen to receive the National Medal of Technology, the highest honor awarded by the President of the United States for technological innovation. In 2006 and 2007, Genzyme was selected by FORTUNE as one of the "100 Best Companies to Work for" in the United States.

With many established products and services helping patients in nearly 90 countries, Genzyme is a leader in the effort to develop and apply the most advanced technologies in the life sciences. The company's products and services are focused on rare inherited disorders, kidney disease, orthopaedics, cancer, transplant, and diagnostic testing. Genzyme's commitment to innovation continues today with a substantial development program focused on these fields, as well as immune disease, infectious disease, and other areas of unmet medical need.

Genzyme Hosts Investor Call This Morning

Genzyme will host an investor call with Professor Alastair Compston this morning, Monday, October 15, from 8:30-9:30 a.m. EST. Three-year, top-line data from the Phase 2 study will be presented and there will be opportunity for investors to ask questions of the alemtuzumab investigator.

To participate in the call, please dial 1-888-889-4416 in the U.S. or 1-773-756-0616 outside of the U.S. The participant passcode is "Genzyme."

A replay of this call will be available by dialing 203-369-3276. This call will also be available live on the investor events section of http://www.genzyme.com. Replays
'/>"/>

SOURCE Genzyme Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
2. Medivation to Host Conference Call to Discuss Top-Line 12-Month Results From Dimebon Alzheimers Disease Study
3. Evotec AG (DE) - Evotec Reports Positive Proof-of-Concept Top-Line Results with ...
4. Evotec Reports Positive Proof-of-Concept Top-Line Results with Insomnia Drug Candidate EVT 201
5. Peregrine Pharmaceuticals Reports Positive Top-Line Results in Bavituximab Combination Therapy Trial in Advanced Cancer Patients
6. Catalyst Pharmaceutical Partners, Inc. Announces Top-Line Results of Its Bioequivalence Study of CPP-109 (Vigabatrin), the Companys Investigational Drug to Treat Cocaine and Methamphetamine Addiction
7. Cobalis Expects to Report Phase III Top-Line Results in May
8. XenoPort Reports Positive Top-Line Phase 3 Trial Results of XP13512 in Restless Legs Syndrome
9. Amarin Reports Top-Line Results of two Phase III Studies of Miraxion in Huntingtons Disease
10. UCB Announces Positive Top-Line Phase III Results for Keppra as Adjunctive Therapy for Partial Onset Seizures in Paediatric Patients from One Month to Less than Four Years of Age
11. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Dose Escalation Trial with Tovaxin for Multiple Sclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... , Feb. 26, 2015 Integrity Applications, ... the GlucoTrack ® model DF-F, a noninvasive  device that ... Lutz Heinemann , Ph.D., will head its new scientific ... leaders in the field of Diabetes research, monitoring and ... Ph.D has been Chief Executive Officer and Head, Business ...
(Date:2/26/2015)... February 26, 2015 Vectorious ... cardiac monitoring system for patients suffering from congestive ... closed a $5 million financing round. Investors in ... owned jointly by Yehuda Zisapel and Prof. ... Gilon, Gur Muntzer and others; and the U.S.-based ...
(Date:2/26/2015)... 2015 Columbia Laboratories, Inc. (Nasdaq: ... specialty pharmaceutical company focused on the development of ... Phase II clinical trial for COL-1077, a lidocaine ... endometrial biopsy in the second quarter of 2015. ... feedback from the United States Food and Drug ...
Breaking Medicine Technology:Integrity Applications Names Prof. Lutz Heinemann to Advisory Board 2Integrity Applications Names Prof. Lutz Heinemann to Advisory Board 3Integrity Applications Names Prof. Lutz Heinemann to Advisory Board 4Vectorious Medical Technologies Completes $5M Raise 2Columbia Laboratories to Initiate a Phase II Clinical Trial for COL-1077, Lidocaine Bioadhesive 10% Gel, in the Second Quarter of 2015 2Columbia Laboratories to Initiate a Phase II Clinical Trial for COL-1077, Lidocaine Bioadhesive 10% Gel, in the Second Quarter of 2015 3
... Society of NeuroInterventional Surgery ... Annual ... from,the US and Argentina reveal that a new minimally invasive procedure,successfully ... that, in severe form, can cripple sufferers.,Announced today at the Society ...
... 29 Echo Therapeutics,(OTC Bulletin Board: ECTE) ... of its Symphony(TM) Transdermal Continuous Glucose Monitoring ... Type 2 Diabetes. Echo,s non-invasive,Symphony tCGM System ... technologies and the Prelude(TM) SkinPrep System, which,incorporates ...
Cached Medicine Technology:New Minimally Invasive Surgical Procedure Restores Quality of Life in Patients With Potentially Debilitating Spinal Condition 2New Minimally Invasive Surgical Procedure Restores Quality of Life in Patients With Potentially Debilitating Spinal Condition 3Echo Therapeutics Announces Positive Results of a Clinical Study of its Symphony(TM) Transdermal Continuous Glucose Monitoring System in Patients with Type 1 and Type 2 Diabetes 2Echo Therapeutics Announces Positive Results of a Clinical Study of its Symphony(TM) Transdermal Continuous Glucose Monitoring System in Patients with Type 1 and Type 2 Diabetes 3Echo Therapeutics Announces Positive Results of a Clinical Study of its Symphony(TM) Transdermal Continuous Glucose Monitoring System in Patients with Type 1 and Type 2 Diabetes 4
(Date:2/26/2015)... February 26, 2015 March is sure ... of Traditional Chinese Medicine (ACTCM). ACTCM is announcing their ... the Chinese New Year celebration and including several webinars, ... as follows: , Sunday, March 1 – ACTCM Chinese ... celebrates the Chinese New Year with lion dancers, free ...
(Date:2/26/2015)... February 26, 2015 As the great ... looking for deeper meaning, more substantial roles and connections ... how do I live a life that still matters? ... of Younger Next Year Total Immersion Retreat , ... program boasts unbelievable results and jump-starts a healthier life. ...
(Date:2/26/2015)... February 26, 2015 “In the last ... monitored the evolution of one of the newest hair ... ARTAS system offers a machinery that facilitates the ... the patient’s scalp,” said Dr. Parsa Mohebi. , Although ... the speed at which the device extracted these grafts ...
(Date:2/26/2015)... (PRWEB) February 26, 2015 Dr. Parsa Mohebi, ... his hair transplant contest winner’s surgery on Friday, ... winner Marc R., is all set to receive his grand ... ARTAS system. His procedure will be done on a live ... To watch the surgery, go to the website and experience ...
(Date:2/26/2015)... 26, 2015 Thousands of people in ... fund powerful progress for the Muscular Dystrophy Association during ... funds and awareness that will help save and improve ... , “MDA Muscle Walk events unite and rally communities ... abilities to move are compromised — including everyday abilities ...
Breaking Medicine News(10 mins):Health News:ACTCM Announces March Schedule of Events 2Health News:The Aspen Club on Actively Aging: Telling a New Story on Aging 2Health News:Newest Technology now Available at Parsa Mohebi Hair Restoration 2Health News:Hair Transplant Contest Winner’s Surgery to be Streamed LIVE 2Health News:MDA Kicks-Off Annual Muscle Walk Season in Local Communities Nationwide to Fight Back Against Muscle Disease 2Health News:MDA Kicks-Off Annual Muscle Walk Season in Local Communities Nationwide to Fight Back Against Muscle Disease 3
... ... , ... 16, 2010 -- PureSafety , a leading provider of results-driven software and information solutions ... health and safety (EHS) professionals, today announced the launch of Future Leaders in EHS ...
... , INNISBROOK, Fla., Feb. 16 ... representing the world,s finest and details of an enhanced week-long tournament ... the connection between healthy sight and optimum sports performance. , Most ... Stricker , Jim Furyk and Kenny Perry ...
... Health and the University of Colorado School of Medicine have ... remarkably effective in mice. In the February 16 issue of ... ( PNAS ), Kimberly Jordan, PhD, Jill Slansky, PhD, and ... vaccinated with a peptide they developed remained alive and tumor-free ...
... drugs often hit other non-cancerous cells, causing patients to get ... just the cancer cells? Researchers at the Georgia Institute of ... just that. In the online journal BMC Cancer ... 100 nanometers in size - to sneak a particular type ...
... study has revealed that certain breast cancer genetic variants ... density and breast cancer. Professor John Hopper of ... greatly in their underlying risk of breast cancer. "These ... the development of breast cancer." "We hope our ...
... Bethesda, MD (Feb. 16, 2010) Certain patients ... and Crohn,s disease of the colon, have an ... individuals without IBD. A number of factors contribute ... individualized and sensible approach to surveillance in patients, ...
Cached Medicine News:Health News:PureSafety and EHS Today Launch Future Leaders in EHS 2Health News:PureSafety and EHS Today Launch Future Leaders in EHS 3Health News:Transitions Championship Announces Strongest Field to Date and a Vision Like No Other on the PGA TOUR(R) 2Health News:Transitions Championship Announces Strongest Field to Date and a Vision Like No Other on the PGA TOUR(R) 3Health News:Transitions Championship Announces Strongest Field to Date and a Vision Like No Other on the PGA TOUR(R) 4Health News:Transitions Championship Announces Strongest Field to Date and a Vision Like No Other on the PGA TOUR(R) 5Health News:New strategy produces promising advance in cancer vaccines 2Health News:Attacking cancer cells with hydrogel nanoparticles 2Health News:Study reveals genetic link between mammographic density and breast cancer 2Health News:AGA offers new recommendations for CRC surveillance for certain patients with IBD 2Health News:AGA offers new recommendations for CRC surveillance for certain patients with IBD 3
... qualitative assay for rapid detection of Strep A ... A test excels at detection of Strep A ... samples. This CLIA Waived test uses a convenient ... A leaves little chance for misdiagnosis, minimizing the ...
The NOW Flu A test is the most frequently adopted rapid flu test on the market today. Testing could not be easier and the results are available in 15 minutes. Now you can focus on the results and tre...
...
... is designed to meet the most demanding ... being one of the safest, most comfortable, ... routine wax sections and specialized resin work, ... quality sections without the the inconvenience of ...
Medicine Products: